RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - RAF proto-oncogene serine/threonine-protein kinase or proto-oncogene c-RAF is an enzyme is encoded by the RAF1 gene. Once activated the cellular RAF1 protein can phosphorylate to activate the dual specificity protein kinases MEK1 and MEK2 which in turn phosphorylate to activate the serine/threonine specific protein kinases, ERK1 and ERK2. It plays an important role in the control of gene expression involved in the cell division cycle, apoptosis, cell differentiation and cell migration.
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) pipeline Target constitutes close to 14 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 4 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Non-Small Cell Lung Cancer, Solid Tumor, Colorectal Cancer, Melanoma, Breast Cancer, Liver Cancer, Metastatic Melanoma, Pancreatic Cancer, Bladder Cancer, Colon Cancer, Gastrointestinal Stromal Tumor (GIST), Hepatocellular Carcinoma, Kidney Cancer (Renal Cell Cancer), Low-Grade Glioma, Lung Adenocarcinoma, Lung Cancer, Metastatic Ovarian Cancer, Multiple Myeloma (Kahler Disease) and Sarcomas.
The latest report RAF Proto Oncogene SerineThreonine Protein Kinase - Pipeline Review, H1 2018, outlays comprehensive information on the RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note : Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1)
- The report reviews RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Pipeline Review, H1 2018
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Overview
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
Basilea Pharmaceutica Ltd
CBT Pharmaceuticals Inc
Chugai Pharmaceutical Co Ltd
Hanmi Pharmaceuticals Co Ltd
Millennium Pharmaceuticals Inc
Novartis AG
Redx Pharma Plc
VG Life Sciences Inc
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Drug Profiles
(MG-005 + sorafenib) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAL-3833 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CBT-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DCBCI-0902 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FYA-1001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-95573 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hydroxychloroquine + sorafenib tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LXH-254 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REDX-05358 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-7304 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit RAF1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CRAF and BRAF for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Pan-RAF Kinase for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-580 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Dormant Products
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Discontinued Products
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
May 05, 2017: Hanmi Pharmaceutical Announced IND Approval of HM95573, a Novel Oral RAF inhibitor
Jan 06, 2017: Hanmi presents pan-RAF inhibitor preclinical trial results at Europe Cancer Symposium
Jun 17, 2016: Hanmi presented the clinical trial results of targeted anti-cancer drug HM95573 at ASCO
Jun 09, 2016: Basilea reports presentation of data on clinical oncology program BAL3833 at ASCO meeting
Apr 21, 2016: Basilea reports presentation of data on clinical oncology program BAL3833 at AACR meeting
Jun 22, 2015: VG Life Sciences Granted Combination Cancer Drug Patent
Nov 10, 2014: Hanmi To Initiate A Phase 1 Clinical Trial Of HM95573, The Next Generation Targeted Therapy For Melanoma Treatment
Sep 04, 2014: VG Life Sciences Progress Update Phase I Cancer Study
Mar 14, 2014: VG Life Sciences's Reports on Clinical Outcomes in Phase I Cancer Study
Dec 13, 2013: VG Life Sciences Update on Phase I Cancer Study
Jul 25, 2013: VG Life Sciences Reports on Scientific Advancements: Completion of Third Cohort of Phase I Clinical Trial; Grant from the American Heart Association;
Apr 04, 2013: VG Life Sciences Reports Positive Safety Results Of Hydroxychloroquine And Sorafenib Combination Therapy In Second Cohort Of Phase I Solid Tumor Study
Jan 31, 2013: VG Life Sciences Reports Positive Results From Phase I Ovarian Cancer Trial Using Sorafenib Combined With Hydroxychloroquine
Jan 14, 2013: VG Life Sciences Receives IRB Approval To Expand Phase I Cancer Trial Of Hydroxychloroquine In Combination With Sorafenib
Jul 19, 2012: Viral Genetics Begins Phase I Clinical Trial For Ovarian Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Basilea Pharmaceutica Ltd, H1 2018
Pipeline by CBT Pharmaceuticals Inc, H1 2018
Pipeline by Chugai Pharmaceutical Co Ltd, H1 2018
Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018
Pipeline by Millennium Pharmaceuticals Inc, H1 2018
Pipeline by Novartis AG, H1 2018
Pipeline by Redx Pharma Plc, H1 2018
Pipeline by VG Life Sciences Inc, H1 2018
Dormant Projects, H1 2018
Discontinued Products, H1 2018
List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administrations, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
Global Erythrocyte Catalase Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 84
The global Erythrocyte Catalase market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Erythrocyte Catalase is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Erythrocyte Catalase is estimated to increase from $ million in 2023 to reach $ millio......
Global Endoenzyme Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 88
The global Endoenzyme market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
The application scenarios of endozymes are very wide and can be used in many fields such as chemical reagents, medical treatment, and environmental protection. With The continuous development of science and technology, The application scenarios of endozymes will continue to expand. This will further promote......
Global CASP9 Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 76
CASP9 (Caspase 9) is a Protein Coding gene. Diseases associated with CASP9 include Cerebral Hypoxia and Colorectal Cancer. Among its related pathways are TNFR1 Pathway and Apoptosis and survival FAS signaling cascades. Gene Ontology (GO) annotations related to this gene include protein kinase binding and peptidase activity. An important paralog of this gene is CASP2.
The global CASP9 market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing......
Global Collagenase Market Research Report 2024
Published: 08-Jan-2024 Price: US 2900 Onwards Pages: 78
Collagenase, obtained from Clostridium histolyticum, is an enzyme used for tissue dissociation in vitro and thus for isolation of many different types of cells. These isolated cells are then used for numerous clinical and research applications.
The global Collagenase market was valued at US$ 79 million in 2023 and is anticipated to reach US$ 92 million by 2030, witnessing a CAGR of 2.2% during The forecast period 2024-2030.
The global collagenase market is mainly compos......
Global Industrial Enzymes Market Research Report 2024
Published: 08-Jan-2024 Price: US 2900 Onwards Pages: 123
Enzymes are protein molecules functioning as specialized catalysts for chemical reactions. They have contributed greatly to The traditional and modern chemical industry by improving existing processes. Enzymes are natural catalysts. They are produced by living organisms to increase The rate of an immense and diverse set of chemical reactions required for life. They are involved in all processes essential for life such as DNA replication and transcription, protein synthesis, metabolism and signal......
Global Phytases Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 109
According to our LPI (LP Information) latest study, the global Phytases market size was valued at US$ 490.1 million in 2023. With growing demand in downstream market, the Phytases is forecast to a readjusted size of US$ 732.7 million by 2030 with a CAGR of 5.9% during review period.
The research report highlights the growth potential of the global Phytases market. Phytases are expected to show stable growth in the future market. However, product differentiation, reducing costs, and suppl......
Global Trypsin Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 115
According to our LPI (LP Information) latest study, the global Trypsin market size was valued at US$ 214.3 million in 2023. With growing demand in downstream market, the Trypsin is forecast to a readjusted size of US$ 374.5 million by 2030 with a CAGR of 8.3% during review period.
The research report highlights the growth potential of the global Trypsin market. Trypsin are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply ch......
Global Cellulase Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 116
According to our LPI (LP Information) latest study, the global Cellulase market size was valued at US$ 1980 million in 2023. With growing demand in downstream market, the Cellulase is forecast to a readjusted size of US$ 3084 million by 2030 with a CAGR of 6.5% during review period.
The research report highlights the growth potential of the global Cellulase market. Cellulase are expected to show stable growth in the future market. However, product differentiation, reducing costs, and sup......
Global Restriction Endonucleases Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 107
According to our LPI (LP Information) latest study, the global Restriction Endonucleases market size was valued at US$ 263.7 million in 2023. With growing demand in downstream market, the Restriction Endonucleases is forecast to a readjusted size of US$ 397 million by 2030 with a CAGR of 6.0% during review period.
The research report highlights the growth potential of the global Restriction Endonucleases market. Restriction Endonucleases are expected to show stable growth in the future m......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
